The genetic foundation of inter individual variability in drug response in terms of efficacy and toxicity is referred to as pharmacogenomics. Pharmacogenomics aspires to reinvent disease management and patient stratification, with clear implications not only for patient quality of life but also for lowering overall health-care costs. The latter has far-reaching ramifications in both clinical and public health settings. Whether it's rare variants, common variants that don't always correlate to a symptom, or variants of unknown significance, pharmacogenomic findings vastly outstrip the field's ability to make sense of them. Pharmacogenomics is a branch of pharmacology that studies the links between genes and pharmacological effects, with the goal of “personalizing” medical treatment.
Title : Engineered nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Preparation and characterization of fibers made from PCL/PVP-ChAgG, along with exploring their potential as wound dressings
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Liver biopsy handling of metabolic-associated fatty liver disease (mafld): The children's hospital of eastern ontario grossing protocol
Consolato M Sergi, University of Ottawa, Canada